Pharmacokinetic-pharmacodynamic profiling of four antimicrobials against Gram-negative bacteria collected from Shenyang, China

BMC Infectious Diseases

Research Article

Yun Zhuo Chu¹  Hua Nian¹  Hong Shang¹  Su Fei Tian¹  Guo Quan Sun¹  Bai Yi Chen² 

[1] Department of Laboratory Medicine, The First Hospital of China Medical University, 110001, Shenyang, China;Division of Infectious Diseases, The First Hospital of China Medical University, 110001, Shenyang, China;

关键词: Minimum Inhibitory Concentration;    Levofloxacin;    Imipenem;    Meropenem;    Cefepime;   

DOI  :  10.1186/1471-2334-10-171

 received in 2009-10-08, accepted in 2010-06-15,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundTo examine common antimicrobial regimens used in eradicating certain nosocomial Gram-negative pathogens and determine which ones are likely to be the most suitable as empirical choices in Shenyang, China.MethodsA 5000-subject Monte Carlo simulation was conducted to determine the cumulative fraction of response (CFR) for meropenem, imipenem, cefepime, piperacillin/tazobactam and levofloxacin against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Acinetobacter baumannii and Pseudomonas aeruginosa collected in 2006 and 2007 from Shenyang.ResultsMeropenem and imipenem had the highest CFRs against the Enterobacteriaceae (97%-100%), followed by cefepime. No antibiotic simulated regimen achieved optimal CFR against P. aeruginosa and A. baumannii. Piperacillin/tazobactam dosed at 4.5 g q8h achieved the lowest CFR against all bacteria.ConclusionsThis study suggests that the carbapenems provide the greatest likelihood of clinical success for the Enterobacteriaceae, and combination therapy might be needed when choosing empirical therapy, especially when A. baumannii or P. aeruginosa are suspected.

【 授权许可】

Unknown   
© Chu et al; licensee BioMed Central Ltd. 2010. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.